1.
Case Rep Ophthalmol
; 5(2): 207-11, 2014 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25126075
RESUMO
We hereby report a case of hemorrhagic macular infarction after intravitreal bevacizumab for chronic multifocal central serous chorioretinopathy (CSC). Issues regarding safety and adverse effects of bevacizumab are discussed. To the best of our knowledge, this is the first reported case of hemorrhagic macular infarction after intravitreal bevacizumab for chronic multifocal CSC.